Wegovy and Zepbound tipped to fuel $20B boom in heart failure market

7th January 2025 Uncategorised 0

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect launches of medicines including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy to help add $20 billion to the value of the market in a decade.

More: Wegovy and Zepbound tipped to fuel B boom in heart failure market
Source: fierce